19805 N. CREEK PARKWAY, BOTHELL, WA
James Sapirstein Appointed CEO of Cocrystal Pharma, Inc.
Appoints James Sapirstein, Biopharma Industry Leader with Extensive Antiviral Development Experience, as Chief Executive Officer
Announces Discovery of Pan-Viral Inhibitors Targeting Hantavirus, Bunyavirus and Influenza
Presentation at ICAR 2026 Highlights Mechanism of Action and Clinical Advancement of CDI-988 for the Prevention and Treatment of Norovirus Infection
Receives FDA Fast Track Designation for CDI-988 for Norovirus Infection Treatment and Preventive
Reports 2025 Financial Results and Provides Updates on its Antiviral Drug-Development Programs
Board Member Dr. Anthony Japour Passes Away
Subjects Dosed in Phase 1b Study Evaluating CDI-988 for Norovirus Prevention and Treatment
Q1
FY 2025
Q3
Q2
FY 2024
Effectiveness Notice
Registration Statement for Securities Offered under a Shelf Registration
Prospectus filed pursuant to Rule 424(b)(3)
S-1
Prospectus filed pursuant to Rule 424(b)(5)
Definitive Proxy Statement
Additional Proxy Materials
PRE 14A
Initial Statement of Beneficial Ownership
Statement of Changes in Beneficial Ownership
Correspondence
Submission Upload